While tirzepatide has yet to demonstrate direct cardiovascular risk outcomes in patients without type 2 diabetes, tirzepatide-treated groups did demonstrate reductions in cardiometabolic variables resulting in a significantly lower 10-year predicted ASCVD risk in patients with overweight or obesity without type 2 diabetes in post hoc analysis of the SURMOUNT-1 trial [49]
As a nephrologist, I am referred all cases of RTA and I have perhaps seen only 3 or 4 cases in the last 15 years all of which were not related to diet
Personalized Treatment: The Role of Genetic Testing Individual responses to semaglutide vary significantly based on genetics, with variations in the GLP1R gene (rs6923761) and the GIPR gene (rs1800437) influencing how well patients respond to GLP-1 therapy
The first clinical trial on DPP-4 inhibitors was published in 2002, and subsequent randomized controlled trials (RCTs) demonstrated their efficacy, safety, and tolerability (15, 17)
The treatment is entirely noninvasive and requires little, if any, downtime for recovery
After binding to ACE2 and/or NRP1 receptors, the S-protein is proteolytically pre-activated by human proprotein convertase furin 66
